Search

Your search keyword '"Kirsten Obernier"' showing total 2 results
Start Over Author "Kirsten Obernier" Journal nature
2 results on '"Kirsten Obernier"'

1. Publisher Correction: Evolution of enhanced innate immune evasion by SARS-CoV-2

Author

Lucy G. Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, Lorena Zuliani-Alvarez, Ben Polacco, Adrian Pelin, Jyoti Batra, Matthew V. X. Whelan, Myra Hosmillo, Andrea Fossati, Roberta Ragazzini, Irwin Jungreis, Manisha Ummadi, Ajda Rojc, Jane Turner, Marie L. Bischof, Kirsten Obernier, Hannes Braberg, Margaret Soucheray, Alicia Richards, Kuei-Ho Chen, Bhavya Harjai, Danish Memon, Joseph Hiatt, Romel Rosales, Briana L. McGovern, Aminu Jahun, Jacqueline M. Fabius, Kris White, Ian G. Goodfellow, Yasu Takeuchi, Paola Bonfanti, Kevan Shokat, Natalia Jura, Klim Verba, Mahdad Noursadeghi, Pedro Beltrao, Manolis Kellis, Danielle L. Swaney, Adolfo García-Sastre, Clare Jolly, Greg J. Towers, and Nevan J. Krogan

Subjects
Multidisciplinary
Published
2022

2. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Author

Pedro Beltrao, Phillip P. Sharp, Nevan J. Krogan, Sabrina J. Fletcher, Saker Klippsten, Trey Ideker, Melanie Ott, Bryan L. Roth, Xi Liu, Devin A. Cavero, Djoshkun Shengjuler, Christopher J.P. Mathy, Jason C.J. Chang, Theodore L. Roth, Hannes Braberg, Claudia Hernandez-Armenta, Lisa Miorin, Jyoti Batra, Shizhong Dai, Maliheh Safari, Brian K. Shoichet, Danish Memon, Tia A. Tummino, Marco Vignuzzi, Mark von Zastrow, Manon Eckhardt, Alan D. Frankel, Qiongyu Li, Tanja Kortemme, Nicole A. Wenzell, Zun Zar Chi Naing, Ferdinand Roesch, Nastaran Sadat Savar, Mathieu Hubert, Xi Ping Huang, Elena Moreno, Danica Galonić Fujimori, Jeffrey Z. Guo, Natalia Jura, Kirsten Obernier, Kliment A. Verba, Harmit S. Malik, Hao-Yuan Wang, Michael McGregor, Melanie J. Bennett, Julia Noack, Gwendolyn M. Jang, Paige Haas, Alice Mac Kain, Daniel J. Saltzberg, Mehdi Bouhaddou, Ziyang Zhang, Yongfeng Liu, Inigo Barrio-Hernandez, Yiming Cai, Kris M. White, Kelsey M. Haas, Maya Modak, Stephanie A. Wankowicz, Raphael Trenker, Kevan M. Shokat, Fatima S. Ugur, Shiming Peng, Sai J. Ganesan, Shaeri Mukherjee, Yuan Zhou, Minkyu Kim, John D. Gross, Jack Taunton, Alicia L. Richards, John S. Chorba, Margaret Soucheray, Danielle L. Swaney, Benjamin J. Polacco, Alan Ashworth, Wenqi Shen, Adolfo García-Sastre, Merve Cakir, Ujjwal Rathore, Kala Bharath Pilla, Michael C. O’Neal, Ying Shi, Kevin Lou, Cassandra Koh, Stephen N. Floor, Davide Ruggero, Ilsa T Kirby, Srivats Venkataramanan, Ruth Hüttenhain, Olivier Schwartz, Beril Tutuncuoglu, Christophe d'Enfert, Jose Liboy-Lugo, David A. Agard, Charles S. Craik, Veronica V. Rezelj, Tina Perica, Matthew P. Jacobson, Lorenzo Calviello, Eric Verdin, Yizhu Lin, Jiankun Lyu, Jiewei Xu, Joseph Hiatt, Andrej Sali, Oren S. Rosenberg, Markus Bohn, David E. Gordon, James S. Fraser, Sara Brin Rosenthal, Duygu Kuzuoğlu-Öztürk, Robyn M. Kaake, Jacqueline M. Fabius, Matthew J. O’Meara, Quang Dinh Tran, Advait Subramanian, Thomas Vallet, Bjoern Meyer, James E. Melnyk, Robert M. Stroud, Helene Foussard, Rakesh Ramachandran, David J. Broadhurst, Janet M. Young, and Michael Emerman

Subjects
0301 basic medicine, viruses, Drug Evaluation, Preclinical, Plasma protein binding, Proteomics, medicine.disease_cause, Mass Spectrometry, 0302 clinical medicine, Chlorocebus aethiops, Protein Interaction Mapping, Molecular Targeted Therapy, Protein Interaction Maps, Cloning, Molecular, Letter to the Editor, Coronavirus, Multidisciplinary, 3. Good health, Drug repositioning, 030220 oncology & carcinogenesis, Host-Pathogen Interactions, Coronavirus Infections, Protein Binding, Pneumonia, Viral, Biology, Antiviral Agents, Virus, Betacoronavirus, Viral Proteins, 03 medical and health sciences, Immune system, Protein Domains, medicine, Animals, Humans, Receptors, sigma, Pandemics, Vero Cells, SKP Cullin F-Box Protein Ligases, Innate immune system, SARS-CoV-2, fungi, HEK 293 cells, Drug Repositioning, COVID-19, Virology, Immunity, Innate, COVID-19 Drug Treatment, HEK293 Cells, 030104 developmental biology, Protein Biosynthesis
Abstract

A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19. A human–SARS-CoV-2 protein interaction map highlights cellular processes that are hijacked by the virus and that can be targeted by existing drugs, including inhibitors of mRNA translation and predicted regulators of the sigma receptors.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results